港股上市公司药明生物（02269）今日盘中大涨5.15%，引起市场广泛关注。此次上涨主要受到公司发布的业绩报告及多家券商上调目标价的利好消息推动。
根据公司最新财报，药明生物2024年下半年业绩表现亮眼。数据显示，公司下半年收入同比增长18%，调整后非国际财务报告准则净利润同比增长36%，符合市场预期。临床前项目增长尤为突出，同比增长54.1%，达到40亿元人民币，这主要得益于海外生物技术公司的强劲需求。
展望未来，药明生物对2025年业绩持乐观态度，预计2025年总收入将同比增长12%至15%，其中持续营运业务（不包括爱尔兰疫苗业务收入）将实现15%至17%的同比收入增长，略超市场预期。多家券商对公司前景看好，纷纷上调目标价。其中，里昂将目标价从26港元上调至28.8港元，建银国际更是将目标价由21.9港元大幅上调至30港元，并维持"跑赢大市"评级。这些利好因素共同推动了药明生物股价的强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.